324 related articles for article (PubMed ID: 28366075)
1. Importance of balancing follow-up time and impact of oral-anticoagulant users' selection when evaluating medication adherence in atrial fibrillation patients treated with rivaroxaban and apixaban.
Coleman C; Yuan Z; Schein J; Crivera C; Ashton V; Laliberté F; Lefebvre P; Peterson ED
Curr Med Res Opin; 2017 Jun; 33(6):1033-1043. PubMed ID: 28366075
[TBL] [Abstract][Full Text] [Related]
2. Adherence to Rivaroxaban Compared with Other Oral Anticoagulant Agents Among Patients with Nonvalvular Atrial Fibrillation.
McHorney CA; Ashton V; Laliberté F; Germain G; Wynant W; Crivera C; Schein JR; Lefebvre P; Peterson ED
J Manag Care Spec Pharm; 2017 Sep; 23(9):980-988. PubMed ID: 28854075
[TBL] [Abstract][Full Text] [Related]
3. Adherence to rivaroxaban versus apixaban among patients with non-valvular atrial fibrillation: Analysis of overall population and subgroups of prior oral anticoagulant users.
McHorney CA; Crivera C; Laliberté F; Germain G; Wynant W; Lefebvre P
PLoS One; 2018; 13(4):e0194099. PubMed ID: 29621248
[TBL] [Abstract][Full Text] [Related]
4. Comparison of Adherence to Rivaroxaban Versus Apixaban Among Patients With Atrial Fibrillation.
McHorney CA; Peterson ED; Laliberté F; Germain G; Nelson WW; Crivera C; Schein J; Lefebvre P
Clin Ther; 2016 Nov; 38(11):2477-2488. PubMed ID: 27789043
[TBL] [Abstract][Full Text] [Related]
5. Adherence to Rivaroxaban, Dabigatran, and Apixaban for Stroke Prevention for Newly Diagnosed and Treatment-Naive Atrial Fibrillation Patients: An Update Using 2013-2014 Data.
Brown JD; Shewale AR; Talbert JC
J Manag Care Spec Pharm; 2017 Sep; 23(9):958-967. PubMed ID: 28854077
[TBL] [Abstract][Full Text] [Related]
6. Major bleeding risk and healthcare economic outcomes of non-valvular atrial fibrillation patients newly-initiated with oral anticoagulant therapy in the real-world setting.
Lin J; Trocio J; Gupta K; Mardekian J; Lingohr-Smith M; Menges B; You M; Nadkarni A
J Med Econ; 2017 Sep; 20(9):952-961. PubMed ID: 28604139
[TBL] [Abstract][Full Text] [Related]
7. Comparison of effectiveness and safety of treatment with apixaban vs. other oral anticoagulants among elderly nonvalvular atrial fibrillation patients.
Deitelzweig S; Luo X; Gupta K; Trocio J; Mardekian J; Curtice T; Lingohr-Smith M; Menges B; Lin J
Curr Med Res Opin; 2017 Oct; 33(10):1745-1754. PubMed ID: 28849676
[TBL] [Abstract][Full Text] [Related]
8. Healthcare costs of NVAF patients treated with rivaroxaban and apixaban in the US.
Milentijevic D; Germain G; Laliberté F; Bookhart BK; MacKnight SD; Tsang J; Lefebvre P
J Med Econ; 2020 Nov; 23(11):1365-1374. PubMed ID: 32897766
[TBL] [Abstract][Full Text] [Related]
9. Pharmacy quality alliance measure: adherence to non-warfarin oral anticoagulant medications.
Crivera C; Nelson WW; Bookhart B; Martin S; Germain G; Laliberté F; Schein J; Lefebvre P
Curr Med Res Opin; 2015; 31(10):1889-95. PubMed ID: 26211815
[TBL] [Abstract][Full Text] [Related]
10. Oral anticoagulant persistence in patients with non-valvular atrial fibrillation: A cohort study using primary care data in Germany.
Collings SL; Lefèvre C; Johnson ME; Evans D; Hack G; Stynes G; Maguire A
PLoS One; 2017; 12(10):e0185642. PubMed ID: 29016695
[TBL] [Abstract][Full Text] [Related]
11. Adherence to non-vitamin-K-antagonist oral anticoagulant medications based on the Pharmacy Quality Alliance measure.
McHorney CA; Crivera C; Laliberté F; Nelson WW; Germain G; Bookhart B; Martin S; Schein J; Lefebvre P; Deitelzweig S
Curr Med Res Opin; 2015 Dec; 31(12):2167-73. PubMed ID: 26393483
[TBL] [Abstract][Full Text] [Related]
12. Direct Comparison of Dabigatran, Rivaroxaban, and Apixaban for Effectiveness and Safety in Nonvalvular Atrial Fibrillation.
Noseworthy PA; Yao X; Abraham NS; Sangaralingham LR; McBane RD; Shah ND
Chest; 2016 Dec; 150(6):1302-1312. PubMed ID: 27938741
[TBL] [Abstract][Full Text] [Related]
13. Bleeding risk of apixaban, dabigatran, and low-dose rivaroxaban compared with warfarin in Japanese patients with non-valvular atrial fibrillation: a propensity matched analysis of administrative claims data.
Kohsaka S; Murata T; Izumi N; Katada J; Wang F; Terayama Y
Curr Med Res Opin; 2017 Nov; 33(11):1955-1963. PubMed ID: 28857611
[TBL] [Abstract][Full Text] [Related]
14. Rivaroxaban versus apixaban in non-valvular atrial fibrillation patients with end-stage renal disease or receiving dialysis.
Miao B; Sood N; Bunz TJ; Coleman CI
Eur J Haematol; 2020 Apr; 104(4):328-335. PubMed ID: 31925840
[TBL] [Abstract][Full Text] [Related]
15. Comparison of treatment persistence with different oral anticoagulants in patients with atrial fibrillation.
Forslund T; Wettermark B; Hjemdahl P
Eur J Clin Pharmacol; 2016 Mar; 72(3):329-38. PubMed ID: 26613954
[TBL] [Abstract][Full Text] [Related]
16. Real-world evidence of stroke prevention in patients with nonvalvular atrial fibrillation in the United States: the REVISIT-US study.
Coleman CI; Antz M; Bowrin K; Evers T; Simard EP; Bonnemeier H; Cappato R
Curr Med Res Opin; 2016 Dec; 32(12):2047-2053. PubMed ID: 27633045
[TBL] [Abstract][Full Text] [Related]
17. Risk of major bleeding in patients with non-valvular atrial fibrillation treated with oral anticoagulants: a systematic review of real-world observational studies.
Deitelzweig S; Farmer C; Luo X; Vo L; Li X; Hamilton M; Horblyuk R; Ashaye A
Curr Med Res Opin; 2017 Sep; 33(9):1583-1594. PubMed ID: 28644048
[TBL] [Abstract][Full Text] [Related]
18. Medication persistence and discontinuation of rivaroxaban and dabigatran etexilate among patients with non-valvular atrial fibrillation.
Nelson WW; Song X; Thomson E; Smith DM; Coleman CI; Damaraju CV; Schein JR
Curr Med Res Opin; 2015; 31(10):1831-40. PubMed ID: 26211816
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness and safety of apixaban versus warfarin in non-valvular atrial fibrillation patients in "real-world" clinical practice. A propensity-matched analysis of 76,940 patients.
Li XS; Deitelzweig S; Keshishian A; Hamilton M; Horblyuk R; Gupta K; Luo X; Mardekian J; Friend K; Nadkarni A; Pan X; Lip GYH
Thromb Haemost; 2017 Jun; 117(6):1072-1082. PubMed ID: 28300870
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study.
Nielsen PB; Skjøth F; Søgaard M; Kjældgaard JN; Lip GY; Larsen TB
BMJ; 2017 Feb; 356():j510. PubMed ID: 28188243
[No Abstract] [Full Text] [Related]
[Next] [New Search]
